A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
|Videos|June 10, 2021
What To Know About Aducanumab and Slowing the Progression of Alzheimer Disease
Pharmacy Times spoke to Dr. Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.
Advertisement
Pharmacy Times spoke to Dr.Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.
Advertisement
Related to this article
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Two recent graduates share strategies for standing out in the competitive fellowship application process.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Advertisement
Advertisement